Peri-implant bone remodeling after total hip replacement combined with systemic alendronate treatment: a finite element analysis.
In order to decrease the peri-implant bone loss during the life-time of the implant, oral use of anti-osteoporosis drugs (like bisphosphonates) has been suggested. In this study, bone remodeling parameters identified from clinical trials of alendronate were used to simulate the effect of those drugs used after total hip arthroplasty on the peri-implant bone density. Results of the simulation show that the oral administrated drugs increase bone density around the implant and decreases, at the same time, the micromovements between the implant and the surrounding bone tissue. Incorporation of drug effect in numerical studies of bone remodeling is a promising tool especially to predetermine safe bisphosphonate doses that could be used with orthopedic implants.
Peter
B
B
Center for Orthopedic Research, Swiss Federal Institute of Technology, 1015 Lausanne, Switzerland.
Ramaniraka
N
N
Rakotomanana
L R
LR
Zambelli
P Y
PY
Pioletti
D P
DP
D000284:Administration, Oral; D019386:Alendronate / Q000008:administration & dosage*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D016723:Bone Remodeling / Q000187:drug effects / Q000502:physiology*; D003198:Computer Simulation; D004305:Dose-Response Relationship, Drug; D004360:Drug Therapy, Computer-Assisted / Q000379:methods; D019544:Equipment Failure Analysis / Q000379:methods; D005269:Femur / Q000187:drug effects / Q000503:physiopathology / Q000601:surgery; D020342:Finite Element Analysis; D006622:Hip Prosthesis / Q000009:adverse effects*; D006801:Humans; D008954:Models, Biological; D010024:Osteoporosis / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control*; D011475:Prosthesis Failure; D016459:Prosthesis-Related Infections / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D016896:Treatment Outcome
D019386:Alendronate